Role of Antiplatelet Therapy ForPrevention of Preeclampsia in High Risk Patients

Abstract

Objective: To assess the efficacy of antiplatelet therapy to prevent pre eclampsia in high risk patients.
Methods: This descriptive case series study was carried out at Sir Ganga Ram Hospital, Lahore for duration of 6 months (from 28-11-2018 to 28-05-2019). Total 200 women were enrolled in the study fulfilling the inclusion criteria.Their demographic details were obtained after informed consent.All participants were given 120 mg/day of antiplatelet (Asprin), (NICE Guideline 107).They were followed-up in OPD till 36th week of gestation. If female developed BP≥ 140/90mmHg and proteinuria> 300mg on urine dipstick method, then preeclampsia was labeled. All this information was recorded on predesigned Performa. Complications of antiplatelet therapy like antepartum hemorrhage, acid peptic disease and low platelets were also recorded.
Results: The mean age of all females was 29.87 ± 5.82 years. There were 12(6%) females who had preeclampsia in previous pregnancy, 45(22.5%) were obese cases,16(8%)females had chronic hypertension, 138(69%) females had gestational hypertension and 37(18.5%) cases had gestational diabetes. The complications observed were preeclampsia in 25 (12.5%) cases, hemorrhage in 94(47%), acid peptic
disease in 64(32%) and low platelet in 17(8.5%) cases.
Conclusion: It is concluded that the frequency of preeclampsia was very low among high risk females after having 120mg of Aspirin (antiplatelet therapy) in first trimester but the side effects of antiplatelet therapy do increase with the higher dose.

How to cite: Munir. I. S., Anum S., Sayyed B.Role of Antiplatelet Therapy For Prevention of Preeclampsia in High Risk Patients.
Esculapio 2021;17(03):2